Obesity Linked to Higher Risk for Adverse Events From Nivolumab

The risk for grade 3 and 4 immune-related adverse events, in particular, was only higher among women with obesity receiving nivolumab monotherapy.
Medscape Medical News

source https://www.medscape.com/viewarticle/985325?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost